Literature DB >> 28295188

How we manage iron overload in sickle cell patients.

Thomas D Coates1, John C Wood2.   

Abstract

Blood transfusion plays a prominent role in the management of patients with sickle cell disease (SCD), but causes significant iron overload. As transfusions are used to treat the severe complications of SCD, it remains difficult to distinguish whether organ damage is a consequence of iron overload or is due to the complications treated by transfusion. Better management has resulted in increased survival, but prolonged exposure to iron puts SCD patients at greater risk for iron-related complications that should be treated. The success of chelation therapy is dominated by patient adherence to prescribed treatment; thus, adjustment of drug regimens to increase adherence to treatment is critical. This review will discuss the current biology of iron homeostasis in patients with SCD and how this informs our clinical approach to treatment. We will present the clinical approach to treatment of iron overload at our centre using serial assessment of organ iron by magnetic resonance imaging.
© 2017 John Wiley & Sons Ltd.

Entities:  

Keywords:  anaemia; chelator; iron overload; management; sickle cell disease

Mesh:

Substances:

Year:  2017        PMID: 28295188      PMCID: PMC5444974          DOI: 10.1111/bjh.14575

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  101 in total

1.  Kinetics of removal and reappearance of non-transferrin-bound plasma iron with deferoxamine therapy.

Authors:  J B Porter; R D Abeysinghe; L Marshall; R C Hider; S Singh
Journal:  Blood       Date:  1996-07-15       Impact factor: 22.113

2.  Chronic transfusion therapy improves but does not normalize systemic and pulmonary vasculopathy in sickle cell disease.

Authors:  Jon A Detterich; Roberta M Kato; Miklos Rabai; Herbert J Meiselman; Thomas D Coates; John C Wood
Journal:  Blood       Date:  2015-06-02       Impact factor: 22.113

3.  Partial manual exchange reduces iron accumulation during chronic red cell transfusions for sickle cell disease.

Authors:  William J Savage; Shirley Reddoch; Jaime Wolfe; James F Casella
Journal:  J Pediatr Hematol Oncol       Date:  2013-08       Impact factor: 1.289

Review 4.  Iron metabolism: interactions with normal and disordered erythropoiesis.

Authors:  Tomas Ganz; Elizabeta Nemeth
Journal:  Cold Spring Harb Perspect Med       Date:  2012-05       Impact factor: 6.915

5.  How I treat transfusional iron overload.

Authors:  A Victor Hoffbrand; Ali Taher; Maria Domenica Cappellini
Journal:  Blood       Date:  2012-08-23       Impact factor: 22.113

Review 6.  Physiology and pathophysiology of iron in hemoglobin-associated diseases.

Authors:  Thomas D Coates
Journal:  Free Radic Biol Med       Date:  2014-04-12       Impact factor: 7.376

7.  Comparative Efficacy and Safety of Oral Iron Chelators and their Novel Combination in Children with Thalassemia.

Authors:  Sunil Gomber; Prachi Jain; Satender Sharma; Manish Narang
Journal:  Indian Pediatr       Date:  2016-03       Impact factor: 1.411

Review 8.  The complex interplay of iron metabolism, reactive oxygen species, and reactive nitrogen species: insights into the potential of various iron therapies to induce oxidative and nitrosative stress.

Authors:  Taija S Koskenkorva-Frank; Günter Weiss; Willem H Koppenol; Susanna Burckhardt
Journal:  Free Radic Biol Med       Date:  2013-09-12       Impact factor: 7.376

9.  Cardiac iron overload in sickle-cell disease.

Authors:  Antonella Meloni; Mammen Puliyel; Alessia Pepe; Vasili Berdoukas; Thomas D Coates; John C Wood
Journal:  Am J Hematol       Date:  2014-04-15       Impact factor: 10.047

10.  Approaching low liver iron burden in chelated patients with non-transfusion-dependent thalassemia: the safety profile of deferasirox.

Authors:  Ali T Taher; John B Porter; Vip Viprakasit; Antonis Kattamis; Suporn Chuncharunee; Pranee Sutcharitchan; Noppadol Siritanaratkul; Raffaella Origa; Zeynep Karakas; Dany Habr; Zewen Zhu; M Domenica Cappellini
Journal:  Eur J Haematol       Date:  2014-03-25       Impact factor: 2.997

View more
  19 in total

1.  MRI-based R2* mapping in patients with suspected or known iron overload.

Authors:  Emre Aslan; Jack W Luo; An Lesage; Philippe Paquin; Milena Cerny; Anne Shu-Lei Chin; Damien Olivié; Guillaume Gilbert; Denis Soulières; An Tang
Journal:  Abdom Radiol (NY)       Date:  2021-01-02

2.  Diagnosis of Systemic Diseases Using Infrared Spectroscopy: Detection of Iron Overload in Plasma-Preliminary Study.

Authors:  Leonardo Barbosa Leal; Marcelo Saito Nogueira; Jandinay Gonzaga Alexandre Mageski; Thiago Pereira Martini; Valério Garrone Barauna; Leonardo Dos Santos; Luis Felipe das Chagas E Silva de Carvalho
Journal:  Biol Trace Elem Res       Date:  2021-01-07       Impact factor: 3.738

3.  Iron overload in transfusion-dependent patients.

Authors:  Thomas D Coates
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

Review 4.  Molecular mechanisms of hepatic dysfunction in sickle cell disease: lessons from Townes mouse model.

Authors:  Tirthadipa Pradhan-Sundd; Gregory J Kato; Enrico M Novelli
Journal:  Am J Physiol Cell Physiol       Date:  2022-06-27       Impact factor: 5.282

5.  Frequency, pattern, and associations of renal iron accumulation in sickle/β-thalassemia patients.

Authors:  Antonella Meloni; Luigi Barbuto; Laura Pistoia; Vincenzo Positano; Stefania Renne; Giuseppe Peritore; Priscilla Fina; Anna Spasiano; Massimo Allò; Giuseppe Messina; Tommaso Casini; Antonella Massa; Luigia Romano; Alessia Pepe; Filippo Cademartiri
Journal:  Ann Hematol       Date:  2022-07-11       Impact factor: 4.030

Review 6.  Blood transfusion and iron overload in patients with Sickle Cell Disease (SCD): Personal experience and a short update of diabetes mellitus occurrence.

Authors:  Ashraf T Soliman; Vincenzo De Sanctis; Mohamed Yassin; Awni Alshurafa; Fateen Ata; Abdulqadir Nashwan
Journal:  Acta Biomed       Date:  2022-08-31

7.  Red cell transfusion and alloimmunization in sickle cell disease.

Authors:  Grace E Linder; Stella T Chou
Journal:  Haematologica       Date:  2021-07-01       Impact factor: 9.941

8.  The impact of iron chelation therapy on patients with lower/intermediate IPSS MDS and the prognostic role of elevated serum ferritin in patients with MDS and AML: A meta-analysis.

Authors:  Yuan Yang; Zengwei Tang; Tianli An; Li Zhao
Journal:  Medicine (Baltimore)       Date:  2019-10       Impact factor: 1.889

Review 9.  Economic Evaluation of Chelation Regimens for β-Thalassemia Major: a Systematic Review.

Authors:  Jialian Li; Yong Lin; Xue Li; Jiayou Zhang
Journal:  Mediterr J Hematol Infect Dis       Date:  2019-07-01       Impact factor: 2.576

10.  GSTM1 and Liver Iron Content in Children with Sickle Cell Anemia and Iron Overload.

Authors:  Latika Puri; Jonathan M Flanagan; Guolian Kang; Juan Ding; Wenjian Bi; Beth M McCarville; Ralf B Loeffler; Aaryani Tipirneni-Sajja; Martha Villavicencio; Kristine R Crews; Claudia M Hillenbrand; Jane S Hankins
Journal:  J Clin Med       Date:  2019-11-05       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.